Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences, Inc. (ENSC)
:ENSC
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.02Last Year’s EPS
-3.3Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -1.45%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.Company Guidance
During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
FDA Breakthrough Therapy Designation
PF614-MPAR received breakthrough therapy designation from the FDA in January 2024, an exclusive classification that has been granted to less than 300 drugs.
Positive Phase II Studies
Completed Phase II trials for PF614 demonstrated efficacy in pain relief and provided data supporting Phase III study designs.
Strong Intellectual Property Portfolio
Ensysce has a global intellectual property portfolio of over 100 patents issued in 25 countries, ensuring protection and growth opportunities.
Financial Improvements
The company reduced its net loss from $25.1 million in 2022 to $10.6 million in 2023, indicating better financial management.
ENSC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ENSC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $2.07 | $2.31 | +11.59% |
Mar 10, 2025 | $4.83 | $4.60 | -4.76% |
Nov 12, 2024 | $10.12 | $10.64 | +5.14% |
Aug 14, 2024 | $5.85 | $5.90 | +0.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ensysce Biosciences, Inc. (ENSC) report earnings?
Ensysce Biosciences, Inc. (ENSC) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Ensysce Biosciences, Inc. (ENSC) earnings time?
Ensysce Biosciences, Inc. (ENSC) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ENSC EPS forecast?
ENSC EPS forecast for the fiscal quarter 2025 (Q2) is -1.02.